1. Introduction {#sec1}
===============

Lung cancer is the principal cause of cancer-associated deaths among males both in developed and in developing countries, and it has exceeded the breast cancer becoming the major cause of cancer-related deaths in females in the developed countries \[[@B1]\]. Non-small cell lung cancer (NSCLC) is a major type of lung cancer that is responsible for 85% lung cancer-associated deaths. Smoking has been recognized as a primary environmental risk factor of lung cancer. However, only a small number of smokers will develop into lung cancer patients.

MicroRNA is a group of 19--22 nucleotide, small, single-stranded, and conserved noncoding RNA that acts as a regulator of gene expression at both the posttranscriptional and the translational levels through acting on the 3′-untranslated region (UTR) of messenger RNA (mRNA) \[[@B2]\]. MiRNAs play important roles in various biological processes associated with the tumorigenesis such as the cellular proliferation, differentiation, metabolism, and apoptosis \[[@B3], [@B4]\]. It is available to isolate the miRNAs from the clinical specimens including the plasma, serum, sputum, and tissue. Meanwhile, it has a high stability. Due to these advantages, the miRNAs are increasingly becoming an ideal tool for the detection of NSCLC.

Recently, a series of articles have shown that different miRNAs might be applied to detect the NSCLC \[[@B45]--[@B57]\]. For example, miR-21, an oncogenic miRNA, has been shown to be overexpressed in lung cancer as well as other various human tumors \[[@B5]\]. Upregulation of miR-21 could promote the tumorigenesis of lung cancer through inhibiting the apoptosis process and negatively regulating the Ras/MEK/ERK signal pathway \[[@B6]\]. High miR-210 expression was correlated with the increased lymph node metastasis and a poor prognosis in patients with NSCLC \[[@B7]\]. Both these two, miR-21 and miR-210, have been explored to be used as diagnostic tools for NSCLC, no matter whether they are applied in combination with other miRNAs or alone \[[@B15]--[@B67]\]. However, as a result of the small sample sizes, the different miRNAs profiling, and the differences of the specimen and ethnicity, inconsistencies existed among studies that had examined the diagnostic value of miR-21, miR-210, and other miRNAs for NSCLC. Therefore, a meta-analysis was performed to assess the performance of miRNAs in the detection for NSCLC.

2. Materials and Methods {#sec2}
========================

2.1. Search Strategy {#sec2.1}
--------------------

Our meta-analysis was based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). We searched PubMed, Google Scholar, Chinese National Knowledge Infrastructure (CNKI), Embase, and Medline to find all associated articles in order to investigate the potential utility of miRNAs as diagnostic tools for NSCLC. The combination of the Medical Subject Headings (MeSH) and the keywords ("lung neoplasm" OR "lung malignancy" OR "lung cancer") AND ("miRNA" OR "microRNAs") AND ("ROC curve" OR "sensitivity" OR "specificity" OR "diagnosis") was used (updated to April 5, 2017). The reference lists of the reviews were also searched to obtain all the acceptable articles.

2.2. Study Selection {#sec2.2}
--------------------

A series of criteria were applied for study inclusion and exclusion. For inclusion, the criteria were as follows: (1) patients with NSCLC; (2) the type of the controls being healthy controls (HC) or patients with benign pulmonary diseases (BPD); (3) assessing the diagnostic value of the miRNAs; (4) the possibility of extracting or calculating TP, FP, FN, and TN from the articles. For exclusion, the criteria were as follows: (1) studies that were duplicate publications, reviews, or unrelated; (2) studies without complete data.

2.3. Data Collection and Quality Assessment {#sec2.3}
-------------------------------------------

Two authors collected the data independently as follows: the first author, publication year, and participant demographic characteristics (ethnicity, sample size, mean or median age, smoking status, the types of the controls, and the testing method of controls and cancer); types of the specimen; miRNA profiling and the data used for this meta-analysis (SEN, SPE, TP, FP, FN, and TN). The quality of these articles were assessed with the QUADAS-2 guidelines \[[@B8]\].

2.4. Statistical Analysis {#sec2.4}
-------------------------

All the statistical analyses were conducted by RevMan 5.3 (version 1.4) software and STATA 11.0 (STATA-Corp, College Station, TX, version 11.0) software. The heterogeneity among the selected studies was assessed through the Q test and the I^2^ value \[[@B9]\]. The*P* value for the Q test being less than 0.05 or the I^2^ ≥ 50 % demonstrated that there was heterogeneity among the included studies. The pooled SPE \[TN/(FP+TN)\], SEN \[TP/(FN+TP)\], diagnostic odds ratio (DOR) \[PLR/NLR\], the negative likelihood ratio (NLR) \[(1-SPE)/SPE)\], the positive likelihood ratio (PLR) \[(SEN/(1-SEN)\], and their 95% confidence intervals (95% CIs) were evaluated by a bivariate random-effect-regression model. The SROC curve was constructed and the AUC value was calculated too. A Fagan nomogram was also constructed to evaluate the clinical utility of miRNAs in the diagnosis of NSCLC. Subgroup analyses (grouped by miRNA profiling: single and multiple; smoking status: only smokers, smokers, and nonsmokers (imbalanced between groups), smokers and nonsmokers (balanced between groups), and unknown smoking status; specimen: serum, plasma, whole blood/blood cell, and not blood; ethnicity: Asian, Caucasian, and Caucasian/African; control-type: BPD, HC, and BPD/HC; stage: early stage and no early stage; and case number: large (≥ 50) and small (\< 50)) and meta-regression analysis were used to identify the potential sources of the heterogeneity. The Deeks\' funnel plot asymmetry test was also applied to explore the publication bias, with the*P*value less than 0.01 considered significant \[[@B10]\].

3. Results {#sec3}
==========

3.1. Literature Search and the Studies\' Characteristics {#sec3.1}
--------------------------------------------------------

As shown in [Figure 1(a)](#fig1){ref-type="fig"}, 2594 eligible articles were included, of which 2145 articles were removed as unrelated and duplicate articles. And then 370 reviews were also excluded, leaving 79 articles with full texts, and another 21 articles were then removed through carefully reading: 14 articles met the exclusion criteria and 7 articles did not have the complete data. Ultimately, 58 articles \[[@B45]--[@B57], [@B15]--[@B67], [@B11]--[@B68]\] with 71 studies published from 2009 to 2017 including 9,099 participants (5111 cases with NSCLC and 3988 controls from the healthy individuals and the patients with the benign pulmonary disease (BPD)) were included. The main characteristics of these 71 studies were shown in [Table 1](#tab1){ref-type="table"}. Wang Y\'s article \[[@B57]\], Fan LH\'s article \[[@B47]\], Nadal E\'s article \[[@B39]\], Tang DF\'s article \[[@B26]\], Razzak R\'s article \[[@B67]\], Wang W\'s article \[[@B68]\], Yu L\'s article \[[@B12]\], and Xing LX\'s article \[[@B11]\] included 2 studies. Bediaga\'s article \[[@B22]\] included 3 studies, Wang C\'s article \[[@B40]\] included 4 studies, and the remaining articles \[[@B45], [@B56], [@B15]--[@B65], [@B13]--[@B21], [@B23]--[@B25], [@B27]--[@B38], [@B41]--[@B46], [@B48]--[@B66]\] included 1 study, respectively. Meanwhile, there were 18 studies \[[@B65], [@B67], [@B22], [@B25], [@B27], [@B39], [@B40], [@B42], [@B49], [@B51], [@B61], [@B63], [@B64]\] performed in Caucasian, 11 studies \[[@B11], [@B12], [@B14], [@B17], [@B21], [@B23], [@B24], [@B32], [@B38]\] performed in Caucasian/African, and 1 study \[[@B20]\] performed in African populations; the remaining studies were performed in Asian populations. A total of 50 studies detected the miRNAs in blood such as the whole blood, plasma, serum, and peripheral blood mononuclear cells (PBMC) \[[@B56], [@B57], [@B15], [@B13]--[@B18], [@B20], [@B23]--[@B29], [@B31], [@B33]--[@B36], [@B38]--[@B41], [@B43]--[@B49], [@B51]--[@B62], [@B64]--[@B68]\], while the remaining studies were detected in nonblood samples (7 tissue \[[@B45], [@B19], [@B22], [@B50], [@B68]\], 1 pleural effusion \[[@B37]\], 12 sputum \[[@B53], [@B67], [@B11], [@B12], [@B21], [@B30], [@B32], [@B42], [@B63]\], and 1 BAL \[[@B65]\]). We evaluated 45 studies for assessing the diagnostic value of multiple miRNAs and 26 studies \[[@B45], [@B56], [@B15], [@B13], [@B16], [@B18]--[@B20], [@B27]--[@B31], [@B33]--[@B35], [@B37], [@B41], [@B44], [@B46], [@B50], [@B52], [@B54], [@B58], [@B66], [@B68]\] of single miRNA.

The quantitative real-time polymerase chain reaction (qRT-PCR) and digital polymerase chain reaction (digital PCR) were used in these studies to test the expression levels of different miRNAs, and the most common reference miRNAs were RNU6B, miR-39, and miR-16. Quality of the enrolled studies summarized in [Figure 1(b)](#fig1){ref-type="fig"} was generally good.

3.2. Pooled Diagnostic Performance {#sec3.2}
----------------------------------

Significant heterogeneity was obtained since I^2^ values for SEN and SPE were 89.05% (95% CI: 87.07-91.03%) and 79.59% (95% CI: 75.18-84.01%), respectively. Therefore, a random-effect model was conducted for this study. Results indicated the pooled SEN and SPE for these 71 studies were 85% (95% CI: 82-88%) and 88% (95% CI: 85-90%), respectively ([Figure 2](#fig2){ref-type="fig"}). The PLR and NLR were 6.9 (95% CI: 5.6-8.4) and 0.17 (95% CI: 0.14-0.21), respectively ([Figure 3](#fig3){ref-type="fig"}), the DOR was 40 (95% CI: 28-58), and the AUC was 0.93 (95% CI: 0.90-0.95) ([Figure 4(a)](#fig4){ref-type="fig"}).

3.3. Publication Bias {#sec3.3}
---------------------

Results of the Deeks\' funnel plot asymmetry test showed that the publication bias did not exist in these studies as the funnel plot was symmetry ([Figure 4(b)](#fig4){ref-type="fig"}) and*P* value equaled 0.12.

3.4. Subgroup Analyses and Meta-Regression Analysis {#sec3.4}
---------------------------------------------------

Results of the meta-regression analysis demonstrated that the heterogeneity might be explained by miRNA profiling (*P*\< 0.001) and case number (*P*\< 0.05) for SPE and by miRNA profiling (*P*\< 0.01) for SEN as described in [Figure 5](#fig5){ref-type="fig"}. The subgroup analyses were also conducted and the results were presented in [Table 2](#tab2){ref-type="table"}. For the subgroups of smoking status, compared with the subgroup of only smokers (SEN: 80% (95% CI: 70-87%), SPE: 86% (95% CI: 77-91%), and AUC: 0.90 (95% CI: 0.87-0.92)), miRNAs had a higher diagnostic efficacy in the subgroups of smokers and nonsmokers (SEN: 88% (95% CI: 74-95%), SPE: 90% (95% CI: 73-97%), and AUC: 0.95 (95% CI: 0.93-0.97) for imbalanced groups and SEN: 83% (95% CI: 74-90%), SPE: 86% (95% CI: 80-90%), and AUC: 0.91 (95% CI: 0.88-0.93) for balanced groups). Subgroup analysis by specimen showed that studies with serum samples exhibited higher diagnostic accuracy with SEN: 91% (95% CI: 86-95%), SPE: 85% (95% CI: 79-89%), and AUC: 0.94 (95% CI: 0.91-0.95) than studies with plasma samples with the SEN: 82% (95% CI: 76-87%), SPE: 87% (95% CI: 83-90%), and AUC: 0.92 (95% CI: 0.89-0.94) and not blooding samples with the SEN: 80% (95% CI: 72-86%), SPE: 89% (95% CI: 85-93%), and AUC: 0.92 (95% CI: 0.89-0.94), respectively. When compared with the large sample size, miRNA might be a better diagnostic tool for small sample size with SEN: 88% (95% CI: 82-92%), SPE: 91% (95% CI: 88-94%), and AUC: 0.95 (95% CI: 0.93-0.97). In the subgroups for the ethnicity, the miRNAs obtained a better diagnostic value in the Caucasian populations with the SEN: 91% (95% CI: 86-95%), SPE: 92% (95% CI: 87-96%), and AUC: 0.97 (95% CI: 0.95-0.98), respectively, when compared with the Asian populations with the SEN: 82% (95% CI: 77-85%), SPE: 86% (95% CI: 82-88%), and AUC: 0.91 (95% CI: 0.88-0.93), respectively, and the Caucasian/African populations with SEN: 85% (95% CI: 72-93%), SPE: 87% (95% CI: 81-91%), and AUC: 0.92 (95% CI: 0.89-0.94), respectively. In the subgroups of the miRNAs profiling, the multiple miRNAs had a higher accuracy for diagnosing the NSCLC with SEN: 88% (95% CI: 85-91%), SPE: 91% (95% CI: 88-93%), and AUC: 0.96 (95% CI: 0.93-0.97), respectively, when compared with the single miRNA with the SEN: 77% (95% CI: 71-82%), SPE: 80% (95% CI: 77-84%), and AUC: 0.86 (95% CI: 0.82-0.88), respectively. miRNAs had a higher value to distinguish the NSCLC patients from healthy individuals with the SEN: 86% (95% CI: 82-89%), SPE: 88% (95% CI: 85-91%), and AUC: 0.94 (95% CI: 0.91-0.95) than controls with benign pulmonary disease with SEN: 84% (95% CI: 77-89%), SPE: 84% (95% CI: 80-88%), and AUC: 0.90 (95% CI: 0.87-0.92). Compared with other miRNAs, miR-210 and miR-21 were more often used as diagnostic tools. However, they were usually associated with other miRNAs. The sensitivity, specificity, and AUC were, respectively, 77% (95% CI: 72-81%), 93% (95% CI: 88-96%), and 0.91(95% CI: 0.88-0.93) for miR-210 with other miRNAs. The sensitivity, specificity, and AUC of miR-21 with other miRNAs were, respectively, 82% (95% CI: 77-86%), 87% (95% CI: 84-89%), and 0.91 (95% CI: 0.88-0.93).

4. Discussion {#sec4}
=============

Due to the high mortality rate and low survival rate of NSCLC, there is an urgent need for the accurate detection method for the early detection of NSCLC especially for the nonsmoking NSCLC patients. Although miRNAs may have a high diagnostic accuracy according to the previous articles, the clinical utility of the miRNA for diagnosing NSCLC remains controversial. Compared with the previous meta-analyses \[[@B69]--[@B71]\], there were more studies and participants included in this meta-analysis. Our analysis showed the pooled SEN was 85% (95% CI: 82-88%), the pooled SPE was 88% (95% CI: 85-90%), and the AUC was 0.93 (95% CI: 0.90-0.95), suggesting that miRNAs had pretty high diagnostic value for NSCLC. Our results also showed that the pooled DOR was 40 (95% CI: 28-58), indicating that for an individual proved positive by miRNAs the chance of having NSCLC is 40 times higher than the negative ones. For the subgroup analyses, higher accuracy was observed in the multiple miRNA profiling when compared with the single miRNA, which was consistent with the previous conclusions \[[@B69]--[@B71]\]. MiRNAs might have a higher diagnostic efficacy for the nonsmoking NSCLC patients compared with the smoking ones. Meanwhile, differences were also observed among the Caucasian, Asian, and Caucasian/African populations. This result could be supported by the Wang H\'s article \[[@B71]\]. Furthermore, miRNAs from serum samples exhibited higher diagnostic value than miRNAs from other specimen. These results meant that combinations of various miRNAs may be better diagnostic tools than the single miRNA, and miRNA isolated from serum could have a higher diagnostic value for the Caucasian populations when compared with the Asian and Caucasian/African populations. Among the different multiple miRNAs, miR-210 and miR-21 associated with other miRNAs could be used for the detection of NSCLC. However, there were still some limitations that could not be neglected in this meta-analysis such as the heterogeneity among these 71 studies, the different methods in miRNA profiling, the possibility that some articles are missed or not published online.

5. Conclusions {#sec5}
==============

Our meta-analysis showed the practicability of miRNAs for diagnosing NSCLC and demonstrated that the multiple miRNAs might have a relatively high diagnostic value for NSCLC compared with the single miRNA diagnosis. miR-210 and miR-21 could be used as effective tools through combining with other miRNAs. In addition, miRNAs, especially isolated from serum, had a better diagnostic accuracy in Caucasian populations than the Asian populations as well as the Caucasian/African populations. When compared with the smoking NSCLC patients, miRNAs might have a higher diagnostic efficacy for the nonsmoking ones. However, studies on the large samples are still demanded to verify our results.
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![Flow chart of this meta-analysis of miRNAs in NSCLC detection (**a**) and the quality of these included articles according to the QUADAS-2 guidelines: proportion of articles with risk of bias (left) and proportion of articles with concerns regarding applicability (right) (**b**).](BMRI2018-5930951.001){#fig1}

![Forest plots of SEN and SPE for the NSCLC diagnosis. Both the SEN and SPE of each study were shown by squares with the 95% confidence interval shown by the error bars.](BMRI2018-5930951.002){#fig2}

![Fagan plot of PLR and NLR to evaluate the clinical utility of miRNAs for diagnosis of NSCLC.](BMRI2018-5930951.003){#fig3}

![SROC curve of the miRNAs as diagnostic tools for NSCLC (**a**) and the Deeks\' test for assessing the publication bias for miRNAs in the detection of NSCLC (**b**).](BMRI2018-5930951.004){#fig4}

![Forest plots for the meta-regression analysis: SEN and SPE. The factors included miRNA profiling, smoking status, specimen, ethnicity, type of control, case number, and stage.](BMRI2018-5930951.005){#fig5}

###### 

The main features of 71 included studies in this meta-analysis.

  **Study ID**          **Ethnicity**        **Specimen**       **Case**   **Age**   **Control**   **Age**   **Type of control**   **Stage**   **MiRNA profiling**                                                         **SEN (**%**)**   **SPE (**%**)**   **Reference miRNA**    **microRNA assay**   **Smoking status** ~ ~ ^**∗**^ 
  --------------------- -------------------- ------------------ ---------- --------- ------------- --------- --------------------- ----------- --------------------------------------------------------------------------- ----------------- ----------------- ---------------------- -------------------- ---------------------------------
  Zhang H 2017          Asian                plasma             129        59.6      83            60.0      HC                    I-II        miR-145, miR-20a, miR-21, miR-223                                           81.8              90.1              miR-16                 qRT-PCR              3
  Halvorsen A 2016      Caucasian            serum              100        62.6      58            57.6      HC                    I-IV        miR-429, miR-205, miR-200b, miR-203, miR-12, miR-34b                        88.0              71.0              miR-220, miR-19b, U6   qRT-PCR              3
  TaiMei C2016          Asian                blood              110        65.0      52            65.7      HC                    I-III       20 miRNAs~ ~^a^                                                             89.1              100               miR-159a, U6           qRT-PCR              4
  Su KL 2016            Asian                plasma             100        NA        100           NA        HC                    I-III       miR-195                                                                     78.0              86.0              miR-39                 qRT-PCR              3
  Zhu WY 2016           Asian                plasma             112        58.5      40            57.9      HC                    I-III       miR-182, miR-183, miR-210, miR-126                                          81.3              100               U6                     qRT-PCR              2
  Jiang LP 2016         Asian                tissue             154        54.9      63            57.8      BPD                   I-IV        miR-26b                                                                     79.9              79.4              U6                     qRT-PCR              3
  Wang Y 2016           Asian                plasma             82         NA        91            NA        HC                    I-II        miR-532, miR-628, miR-425                                                   91.5              97.8              miR-39                 qRT-PCR              4
  Wang Y 2016           Asian                plasma             36         NA        43            NA        HC                    I-II        miR-532, miR-628, miR-425                                                   97.2              95.3              miR-39                 qRT-PCR              4
  Fan LH 2016           Asian                serum              94         60.5      58            58.1      HC                    I-III       miR-15b, miR-16, miR-20a                                                    86.2              91.4              NA                     qRT-PCR              4
  Fan LH 2016           Asian                serum              70         59.7      54            58.0      HC                    I-III       miR-15b, miR-16, miR-20a                                                    94.3              94.2              NA                     FQDs                 4
  Sun L 2016            Asian                plasma             87         60.7      96            53.8      HC,BPD                I-IV        miR-30a                                                                     61.0              84.3              U6                     qRT-PCR              4
  Su Y 2016             Asian                sputum             144        66.3      171           65.2      BPD                   I           miR-21, miR-31, miR-210                                                     81.5              85.9              U6                     qRT-PCR              1
  Gao X 2016            Asian                plasma             30         61.1      30            60.2      HC                    I           miR-324, miR-1285                                                           93.3              90.0              miR-39                 qRT-PCR              4
  Wang X 2016           Asian                plasma             59         55.9      59            57.6      BPD                   I-III       miR-486                                                                     83.1              78.0              miR-16                 qRT-PCR              4
  Wei J 2016            Asian                plasma             63         61.0      30            57.0      HC                    I-IV        miR-21                                                                      76.2              70.0              miR-16                 qRT-PCR              3
  Razzak 2016           Caucasian            sputum             22         68        10            58        HC,BPD                III-IV      miR-21, miR-210, miR-372                                                    64                100               U6                     qRT-PCR              4
  Razzak 2016           Caucasian            sputum             21         70        10            58        HC,BPD                I-II        miR-21, miR-210, miR-372                                                    67                90                U6                     qRT-PCR              4
  Leidinger P 2016      Caucasian            blood              74         NA        20            NA        HC                    I-III       miR-720, miR-29c, miR-199a, miR-378a,let-7f                                 91.0              98.0              U24,U48                qRT-PCR              4
  Wang WZ 2016          Asian                tissue             15         57        16            58        HC                    I-IV        miR-182, miR-10a, miR-301b, miR-1244, miR-301a, miR-135b, miR-224, miR-21   93.3              93.8              miR-16                 qRT-PCR              4
  Wang WZ 2016          Asian                serum              54         NA        15            NA        HC                    I-IV        miR-1244                                                                    81.5              80                miR-39                 qRT-PCR              4
  Kim JL O 2015         Caucasian            BAL                21         70        10            59        HC,BPD                I-II        miR-21, miR-143, miR-155, miR-210, miR-373                                  85.7              100               U6                     qRT-PCR              4
  Wang C 2015           Asian                serum              19         61.8      19            62.1      HC                    I-IV        miR-483, miR-193a, miR-25, miR-214, miR-7                                   100               84                let-7d/g/i             qRT-PCR              4
  Li WS 2015            Asian                plasma             11         59        11            55        HC                    I-III       mir-486                                                                     90.9              81.8              miR-39, U44            qRT-PCR              4
  Wang C 2015           Asian                serum              63         61.9      63            59.7      HC                    I-IV        miR-483, miR-193a, miR-25, miR-214, miR-7                                   89.0              68.0              let-7d/g/i             qRT-PCR              4
  Wang C 2015           Caucasian            serum              108        67.2      56            63.7      BPD                   I-IV        miR-483, miR-193a, miR-25, miR-214, miR-7                                   95.0              95.0              let-7d/g/i             qRT-PCR              4
  Wang C 2015           Caucasian            serum              108        67.2      48            58.5      HC                    I-IV        miR-483, miR-193a, miR-25, miR-214, miR-7                                   95.0              84.0              let-7d/g/i             qRT-PCR              4
  Nadal E 2015          Caucasian            serum              70         67.5      22            67.0      HC,BPD                I-III       miR-141, miR-200b, miR-193b                                                 96.0              95.0              U6                     qRT-PCR              2
  Nadal E 2015          Caucasian            serum              84         65.5      23            60.0      HC,BPD                I-III       miR-141, miR-200b, miR-193b                                                 97.0              96.0              U6                     qRT-PCR              2
  Guo WG 2015           Asian                plasma             126        NA        50            NA        HC                    I-IV        mir-204                                                                     76.0              82.0              U6                     qRT-PCR              4
  Ma J 2015             Caucasian, African   PBMC               84         64.1      69            62.4      BPD                   I-IV        miR-19b, miR-29b                                                            72.6              82.6              miR-423-3p             qRT-PCR              2
  Li L 2015             Asian                serum              36         56.0      30            58.0      HC,BPD                I-IV        miR-148a, miR-148b, miR-152                                                 72.2              90.0              U6                     qRT-PCR              4
  Zhang XL 2015         Asian                tissue             125        61.0      125           61.0      HC                    I-IV        miR-141                                                                     64.8              64.8              miR-191, miR-103       qRT-PCR              3
  Zhao W 2015           Asian                serum              80         57.6      60            55.4      HC                    NA          miR-21                                                                      73.8              71.7              U6                     qRT-PCR              4
  Wang RJ 2015          Asian                serum              70         64.4      70            63.7      HC                    NA          miR-145                                                                     92.8              61.4              miR-39                 qRT-PCR              3
  Yang JS 2015          Asian                serum              152        NA        300           NA        HC                    I-IV        miR-152, miR-148a, miR-148b, miR-21                                         96.0              91.0              U6                     qRT-PCR              3
  Xing LX 2015          Caucasian            sputum             67         66.4      69            64.9      BPD                   I-II        miR-21, miR-31, miR-210                                                     82.1              88.4              U6, miR-16             qRT-PCR              4
  Liu CM 2015           Asian                Pleural effusion   61         53.8      70            54.4      BPD                   NA          miR-192                                                                     61.3              79.5              U6                     qRT-PCR              2
  Dou HL 2015           Asian                plasma             120        63.2      360           NA        HC                    I-IV        miR-152                                                                     86.0              81.3              U6                     digital PCR          4
  Yang YL 2015          Asian                PBMC               74         62.5      52            61.8      HC                    I-IV        miR-10b                                                                     86.5              76.9              miR-16                 qRT-PCR              3
  Li N 2014             Caucasian, African   sputum             35         68.9      40            65.7      HC                    I           miR-31, miR-210                                                             65.7              85.0              NA                     qRT-PCR              4
  Zhu W 2014            Asian                serum              70         59.0      48            NA        HC                    I-IV        miR-429                                                                     54.3              81.2              U6,U48                 qRT-PCR              4
  LI M 2014             Asian                serum              514        NA        54            NA        HC                    I-IV        miR-499                                                                     73.7              92.7              miR-39                 qRT-PCR              3
  Ulivi P 2013          Caucasian            blood              86         68.0      24            65.0      HC                    I-II        miR-328                                                                     70.0              83.0              U38B,U58A              qRT-PCR              4
  Bediaga 2013          Caucasian            tissue             45         66.4      45            66.4      HC                    I-IV        8 miRNAs~ ~^b^                                                              100               97.8              4miRNAs~ ~^c^          qRT-PCR              3
  Bediaga 2013          Caucasian            tissue             47         67.8      47            67.8      HC                    I-IV        8 miRNAs~ ~^b^                                                              97.5              96.3              4miRNAs~ ~^c^          qRT-PCR              3
  Bediaga 2013          Caucasian            tissue             22         68.4      22            68.4      HC                    I-IV        8 miRNAs~ ~^b^                                                              100               95.0              4miRNAs~ ~^c^          qRT-PCR              3
  Anjuman 2013          Caucasian, African   sputum             39         65.6      42            62.3      BPD                   I           miR-210, miR-31                                                             61.5              90.5              U6                     qRT-PCR              4
  Tang DF 2013          Asian                plasma             62         64.8      60            66.0      HC                    I-III       miR-21, miR-145, miR-155                                                    69.4              78.3              U6                     qRT-PCR              1
  Tang DF 2013          Asian                plasma             34         65.2      32            66.4      HC                    I-III       miR-21, miR-145, miR-155                                                    76.5              81.3              U6                     qRT-PCR              1
  Mozzoni 2013          Caucasian            plasma             54         69.1      46            64.1      BPD                   I-III       miR-21, miR-486                                                             87.0              86.5              miR-16                 qRT-PCR              4
  ZENG XL 2013          Asian                PBMC               64         58.9      26            54.4      HC                    I-IV        miR-143                                                                     75.0              92.3              U6                     qRT-PCR              4
  Yang XQ 2013          Asian                sputum             24         60.5      24            57.8      BPD                   I-IV        let-7a                                                                      87.5              83.3              U6                     digital PCR          4
  Ma J 2013             Caucasian, African   plasma             36         66.7      38            64.6      HC                    I           miR-21, miR-335                                                             71.8              80.6              NA                     qRT-PCR              4
  Cazzoli R 2013        Caucasian, African   plasma             50         66.1      30            64.8      BPD                   I           miR-151a, miR-30a, miR-200b, miR-629, miR-100, miR-154                      96.0              60.0              let7a                  qRT-PCR              2
  Abd-E 2013            African              Serum              65         54.1      37            50.1      HC                    I-II        miR-182                                                                     100               86.5              SNORD68                qRT-PCR              4
  Sanfiorenzo C 2013    Caucasian            plasma             52         65.1      10            68.9      BPD                   I-III       miR-152, miR-145, miR-199a, miR-24, miR-20a, miR-25                         90.9              83.3              miR-192, miR-16        qRT-PCR              4
  Roa Wilson H 2012     Caucasian            sputum             24         68.8      6             44.7      HC                    I-II        miR-21, miR-143, miR-155, miR-210, miR-372                                  83.3              100               U6                     qRT-PCR              4
  Li GJ 2012            Asian                plasma             16         NA        14            NA        BPD                   I           miR-494, miR-22, miR-200b                                                   85.3              94.5              18S                    qRT-PCR              4
  Ma YX 2012            Asian                serum              193        NA        110           NA        HC                    I-IV        miR-125b                                                                    78.2              66.4              NA                     qRT-PCR              4
  Hennessey P 2012      Caucasian, African   serum              55         68.2      75            65.7      HC                    I-IV        miR-15b, miR-27b                                                            100               84.0              miR-16                 qRT-PCR              4
  ZengXL 2012           Asian                PBMC               34         NA        26            54.4      HC                    I-IV        miR-150                                                                     87.5              69.2              U6                     qRT-PCR              4
  Zhao M 2012           Asian                tissue             55         NA        55            NA        HC                    I-IV        miR-29a                                                                     49.1              85.5              U6                     qRT-PCR              3
  Shen J 2011           Caucasian, African   plasma             34         68.0      29            66.0      HC                    I-IV        miR-21, miR-126, miR-210, miR-486                                           91.7              96.6              miR-16                 qRT-PCR              1
  Jeong H 2011          Asian                blood              35         67.0      30            60.0      HC                    I-IV        let-7a                                                                      90.3              90.3              U6                     qRT-PCR              4
  Wei J 2011            Asian                plasma             77         59.6      36            56.4      HC                    I-IV        miR-21                                                                      61.0              83.3              miR-16                 qRT-PCR              3
  Liu S 2011            Asian                plasma             130        53.1      170           57.5      HC                    I-III       miR-126                                                                     46.4              90                NA                     qRT-PCR              3
  Yu L 2010             Caucasian, African   sputum             36         68.2      36            66.7      HC                    I           miR-486, miR-21, miR-200b, miR-375                                          80.6              91.7              U6                     qRT-PCR              4
  Yu L 2010             Caucasian, African   sputum             64         67.0      58            65.0      HC                    I-IV        miR-486, miR-21, miR-200b, miR-375                                          70.3              80.0              U6                     qRT-PCR              3
  Xing LX 2010          Caucasian, African   sputum             48         67.5      48            65.9      HC                    I           miR-205, miR-210, miR-708                                                   73.0              96.0              U6                     qRT-PCR              4
  Xing LX 2010          Caucasian, African   sputum             67         68.0      55            65.0      HC                    I-IV        miR-205, miR-210, miR-708                                                   72.0              95.0              U6                     qRT-PCR              3
  Keller Andreas 2009   Caucasian            blood              17         64.2      19            37.9      HC                    I-III       24miRNAs~ ~^d^                                                              92.5              98.1              NA                     qRT-PCR              4

^a^miR-451, miR-1290, miR-636, miR-30c, miR-22-3p, miR-19b, miR-486-5p, miR-20b, miR-93, miR-34b, miR-185, miR-126-5p, miR-93-3p, miR-1274a, miR-142-5p, miR-628-5p, miR-486-3p, miR-425, miR-645, miR-24; ^b^miR-96, miR-450a, miR-183, miR-9, miR-577, Let-7i, miR-27b and miR-34a; ^c^miR-26a, miR-140-5p, miR-195, miR-30b;  ^d^miR-126, miR-423, miR-15a, let-7d, let-7i, miR-22, miR-98, miR-19a, miR-20b, miR-324, miR-574, miR-195, miR-25, let-7e, let-7c, let-7f, let-7a, let-7g, miR-140, miR-339, miR-361, miR-1283, miR-18a, miR-26b; ^*∗*^1: only smokers; 2: smokers and nonsmokers (smoking status was imbalanced between groups); 3: smokers and nonsmokers (smoking status was balanced between groups); 4: unknown smoking status.

N: number; HC: healthy control; BPD: benign pulmonary disease; miR: microRNA; SEN: sensitivity; SPE: specificity; FQDs: fluorescence quantum dots; BAL: bronchoalveolar lavage.

###### 

Subgroup analyses for the selected studies.

  **Subgroups**                 **No**   **SEN \[95**%**CI\]**   **SPE \[95**%**CI\]**   **PLR\[95**%**CI\]**   **NLR \[95**%**CI\]**   **DOR\[95**%**CI\]**   **AUC \[95**%**CI\]**
  ----------------------------- -------- ----------------------- ----------------------- ---------------------- ----------------------- ---------------------- -----------------------
  MiR profiling                                                                                                                                                 
   single                       26       0.77\[0.71-0.82\]       0.80\[0.77-0.84\]       3.9\[3.3-4.7\]         0.28\[0.22-0.36\]       14\[10-20\]            0.86\[0.82-0.88\]
   multiple                     45       0.88\[0.85-0.91\]       0.91\[0.88-0.93\]       10.0\[7.5-13.3\]       0.13\[0.10-0.17\]       79\[50-126\]           0.96\[0.93-0.97\]
  Smoking status                                                                                                                                                
   only smokers                 4        0.80\[0.70-0.87\]       0.86\[0.77-0.91\]       5.6\[3.2-9.9\]         0.23\[0.14-0.38\]       24\[9-66\]             0.90\[0.87-0.92\]
   S+NS (imbalanced)~ ~^*∗*^    6        0.88\[0.74-0.95\]       0.90\[0.73-0.97\]       9.2\[3.0-28.2\]        0.13\[0.05-0.31\]       71\[14-360\]           0.95\[0.93-0.97\]
   S+NS (balanced)  ~ ~^*∗*^    18       0.83\[0.74-0.90\]       0.86\[0.80-0.90\]       5.9\[3.9-8.8\]         0.19\[0.12-0.32\]       30\[13-69\]            0.91\[0.88-0.93\]
   unknown status               43       0.86\[0.82-0.89\]       0.88\[0.85-0.91\]       7.3\[5.7-9.4\]         0.16\[0.12-0.21\]       46\[30-70\]            0.93\[0.91-0.95\]
  Specimen                                                                                                                                                      
   plasma                       22       0.82\[0.76-0.87\]       0.87\[0.83-0.90\]       6.3\[4.6-8.5\]         0.20\[0.15-0.28\]       31\[18-52\]            0.92\[0.89-0.94\]
   serum                        19       0.91\[0.86-0.95\]       0.85\[0.79-0.89\]       6.1\[4.3-8.5\]         0.10\[0.06-0.17\]       60\[28-128\]           0.94\[0.91-0.95\]
   Whole blood/blood cell       9        0.84\[0.78-0.89\]       0.92\[0.80-0.97\]       10.9\[3.9-30.3\]       0.17\[0.11-0.26\]       64\[17-234\]           0.92\[0.89-0.94\]
   not blood                    21       0.80\[0.72-0.86\]       0.89\[0.85-0.93\]       7.5\[4.9-11.7\]        0.22\[0.16-0.32\]       34\[16-71\]            0.92\[0.89-0.94\]
  Ethnicity                                                                                                                                                     
   Asian                        41       0.82\[0.77-0.85\]       0.86\[0.82-0.88\]       5.7\[4.5-7.2\]         0.21\[0.17-0.27\]       27\[18-40\]            0.91\[0.88-0.93\]
   Caucasian                    18       0.91\[0.86-0.95\]       0.92\[0.87-0.96\]       12\[7.0-20.4\]         0.09\[0.06-0.15\]       127\[54-302\]          0.97\[0.95-0.98\]
   Caucasian/African            12       0.85\[0.72-0.93\]       0.87\[0.81-0.91\]       6.6\[4.6-9.4\]         0.17\[0.09-0.33\]       39\[17-88\]            0.92\[0.89-0.94\]
  Control-type                                                                                                                                                  
   BPD                          13       0.84\[0.77-0.89\]       0.84\[0.80-0.88\]       5.3\[4.1-6.8\]         0.19\[0.13-0.28\]       27\[16-46\]            0.90\[0.87-0.92\]
   HC                           50       0.86\[0.82-0.89\]       0.88\[0.85-0.91\]       7.4\[5.7-9.5\]         0.16\[0.12-0.21\]       47\[30-74\]            0.94\[0.91-0.95\]
   BPD, HC                      8        0.81\[0.67-0.90\]       0.91\[0.79-0.96\]       8.8\[3.4-22.9\]        0.21\[0.11-0.40\]       42\[9-187\]            0.93\[0.90-0.95\]
  Stage                                                                                                                                                         
   I-II                         18       0.84\[0.78-0.89\]       0.90\[0.86-0.93\]       8.3\[5.8-11.9\]        0.17\[0.12-0.25\]       48\[27-87\]            0.94\[0.91-0.96\]
   I-IV                         50       0.86\[0.82-0.89\]       0.88\[0.84-0.90\]       6.5\[5.4-8.7\]         0.16\[0.13-0.22\]       42\[27-66\]            0.93\[0.90-0.95\]
  No. of cases                                                                                                                                                  
   small                        25       0.88\[0.82-0.92\]       0.91\[0.88-0.94\]       10.0\[7.1-14.2\]       0.14\[0.09-0.21\]       74\[38-143\]           0.95\[0.93-0.97\]
   large                        46       0.84\[0.79-0.87\]       0.86\[0.82-0.88\]       5.8\[4.6-7.2\]         0.19\[0.15-0.24\]       31\[20-46\]            0.91\[0.89-0.94\]
  MiR-210                       12       0.77\[0.72-0.81\]       0.93\[0.88-0.96\]       11.0\[6.2-19.4\]       0.25\[0.20-0.31\]       44\[22-87\]            0.91\[0.88-0.93\]
  MiR-21                        16       0.82\[0.77-0.86\]       0.87\[0.84-0.89\]       6.3\[5.0-8.1\]         0.21\[0.15-0.28\]       31\[19-50\]            0.91\[0.88-0.93\]

No: the number of the studies; HC: healthy control; BPD: benign pulmonary disease; SEN: sensitivity; SPE: specificity; PLR: positive likelihood ratio; NLR:negative likelihood ratio; DOR: diagnostic odds ratio; AUC:area under the curve; no. of case: small (\<50) and large (≥50).

 ^*∗*^ S: smokers; NS: nonsmokers; imbalanced: the smoking status was imbalanced between groups; balanced: the smoking status was balanced between groups.
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